BMRA
Biomerica, Inc. (BMRA) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
BMRA’s low leverage and modest current ratio reduce near-term balance-sheet pressure versus more indebted peers, but they do not offset weak operating economics.
The company’s negative ROIC indicates capital is not yet earning its cost, leaving it structurally behind profitable peers on value creation.
A cash position implied by net debt below zero provides some liquidity flexibility versus leveraged competitors, though it remains a secondary advantage in this framework.
Weaknesses
BMRA’s negative ROIC signals persistent underperformance in capital deployment versus peers, which directly weakens long-term competitive positioning.
A cash conversion cycle near 183 days ties up working capital far longer than stronger peers, constraining reinvestment and margin resilience.
The quick ratio below 1.0 suggests limited immediate liquidity versus better-capitalized peers, increasing dependence on operating execution and financing access.
Opportunities
If BMRA shortens its cash conversion cycle, it could release working capital faster than peers and improve funding capacity for growth.
A stronger liquidity profile than highly levered competitors could support selective operational investment, but only if returns on capital improve materially.
Any improvement in capital efficiency would have outsized impact because BMRA starts from a low base relative to peers with stronger profitability.
Threats
Peers with positive returns on invested capital can compound faster, leaving BMRA at a structural disadvantage in reinvestment and market positioning.
Prolonged working-capital intensity raises execution risk versus peers, because cash remains trapped in operations rather than supporting growth or flexibility.
If profitability stays negative, BMRA may remain dependent on external funding while stronger peers self-finance expansion more efficiently.
Overall Score
BMRA’s peer positioning is structurally weak because negative returns on capital and long working-capital cycles outweigh its limited balance-sheet flexibility.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Biomerica, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
